Wednesday, May 10, 2023 1:02:09 PM
Common Stock
The Company is authorized to issue up to 500,000,000 shares of common stock (par value $0.00001). As of September 30, 2022 and 2021, the Company had 374,305,480 shares and 343,237,369 shares of common stock issued and outstanding, respectively.
During the year ended September 30, 2022, the Company issued 31,068,111 shares of common stock as follows:
? 28,868,111 shares of the Company’s common stock to members of the Board of Directors, employees and consultants valued at $13,207,981 ($0.46 per share average).
? 1,000,000 shares of the Company’s common stock at $0.10 per share for a purchase price of $100,000.
? 200,000 shares of the Company’s common stock at $0.22 per share for a purchase price of $21,921 (AUD$30,000).
? 1,000,000 shares issued to settle debt on convertible note that matured on December 5, 2021.
During the year ended September 30, 2021, the Company issued 96,998,646 shares of common stock as follows:
? 12,888,596 shares of the Company’s common stock to members of the Board of Directors, employees and consultants valued at $6,293,500 ($0.49 per share).
? 1,900,000 shares of the Company’s common stock at an average price of $0.073 per share for an aggregate purchase price of $138,093.
? 534,446 shares of the Company’s common stock for the conversion of debt totaling $204,010.
? 50,000,000 shares of the Company’s common stock to EKH International Co. Limited a beneficial entity of Rodney Young valued at $0.55 per share.
? 28,665,604 shares of the Company’s common stock for the acquisition of intangible assets valued at $6,879,745
? 3,000,000 shares of the Company’s common stock for the future liability settlement for assumed liabilities fair value of $720,000 recorded as stock receivable.
______________________________________________
Careful a RS is coming.......
Recent GSTX News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/13/2024 07:34:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 03:25:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 06:59:08 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 01/16/2024 10:00:46 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 12/28/2023 01:59:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 06:24:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/13/2023 04:50:42 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 07:12:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/04/2023 05:53:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/29/2023 04:12:03 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM